FeesSafety
Pluang+

SurgePays inks $48M prepaid wireless deal with Etime system, boosting monthly sales by $4M.

Market News
03 Nov 2026, 16:05 WIB
GlobeNewsWire
View Source
Bullish
SurgePays inks $48M prepaid wireless deal with Etime system, boosting monthly sales by $4M.

SurgePays, a fintech company, signed a prepaid wireless agreement with Etime system committing to at least $48 million in purchase volume from October 2026 to September 2027, with a minimum of $4 million monthly. This deal supports SurgePays' retail sales platform and is already generating new transaction volume. The agreement automatically renews annually, providing SurgePays with a steady growth opportunity in prepaid wireless sales through its POS network. Etime system, serving over 1,000 retail locations, values reliable prepaid wireless access for its merchants, reinforcing confidence in this partnership.

SurgePays' new prepaid wireless agreement provides context for technology sector activity on Pluang. For readers following Technology-sector US stocks, here is Pluang's market snapshot as of Nov 03, 2026 21:01 WIB: out of 150 priced stocks, 80 rose and 69 fell. Notable movers include Entegris Inc (ENTG) at USD 161.00 with a 1-day change of +6.23% and a typical hold time of 42 days, Palantir Technologies Inc (PLTR) at USD 168.01 down -5.79% with 54% sell order activity and a typical hold time of 80 days, and Cipher Mining Inc (CIFR) at USD 7.20 up +4.96% with a balanced order activity and a typical hold time of 16 days.

More News

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...

Company Fundamentals
Bullish
2 hours ago
Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...

Market News
Bullish
2 hours ago
Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...

Market News
Bullish
2 hours ago
Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...

Company Fundamentals
Neutral
3 hours ago
Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...

Company Fundamentals
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App